In the latest trading session,, 3.17 million CRISPR Therapeutics AG (NASDAQ:CRSP) shares changed hands as the company’s beta touched 1.80. With the company’s most recent per share price at $69.19 changing hands around $4.06 or 6.24% at last look, the market valuation stands at $5.98B. CRSP’s last price was a premium, traded about 3.9% off its 52-week high of $66.49. The share price had its 52-week low at $30.04, which suggests the last value was 56.58% up since then. When we look at CRISPR Therapeutics AG’s average trading volume, we note the 10-day average is 4.0 million shares, with the 3-month average coming to 2.82 million.
Analysts gave the CRISPR Therapeutics AG (CRSP) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.93. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended CRSP as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. CRISPR Therapeutics AG’s EPS for the current quarter is expected to be -1.44.
CRISPR Therapeutics AG (NASDAQ:CRSP) trade information
Instantly CRSP is in green as seen in intraday trades today. With action 22.64%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 14.41%, with the 5-day performance at 22.64% in the green. However, in the 30-day time frame, CRISPR Therapeutics AG (NASDAQ:CRSP) is 55.74% up. Looking at the short shares, we see there were 21.41 million shares sold at short interest cover period of 9.74 days.
The consensus price target for the stock as assigned by Wall Street analysts is 65, meaning bulls need a downside of -6.45% from its recent market value. According to analyst projections, CRSP’s forecast low is 65 with 65 as the target high. To hit the forecast high, the stock’s price needs a 6.06% surge from its current level, while the stock would need to tank 6.06% for it to hit the projected low.
CRISPR Therapeutics AG (CRSP) estimates and forecasts
Year-over-year growth is forecast to reach 27.67% up from the last financial year.
Consensus estimates given by 17 financial analysts project the company’s revenue in the current quarter to hit an average of 6.45M. 16 analysts are of the opinion that CRISPR Therapeutics AG’s revenue for the current quarter will be 12.99M. The company’s revenue for the corresponding quarters a year ago was 517k and 602k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 1,146.72%. The estimates for the next quarter sales put growth at 2,058.30%.
The 2025 estimates are for CRISPR Therapeutics AG earnings to decrease by -25.64%, but the outlook for the next 5-year period is at 5.55% per year.
CRSP Dividends
CRISPR Therapeutics AG is expected to release its next quarterly earnings report on 2025-May-06.
CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.69% of CRISPR Therapeutics AG shares while 76.46% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 77.78%. There are 76.46% institutions holding the CRISPR Therapeutics AG stock share, with CAPITAL INTERNATIONAL INVESTORS the top institutional holder. As of 2024-06-30, the company held 9.2619% of the shares, roughly 7.87 million CRSP shares worth $424.8 million.
ARK INVESTMENT MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 9.1597% or 7.78 million shares worth $420.12 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jun 30, 2025 were ARK ETF Trust-ARK Innovation ETF and NEW PERSPECTIVE FUND . With 7.04 shares estimated at $481.02 million under it, the former controlled 8.16% of total outstanding shares. On the other hand, NEW PERSPECTIVE FUND held about 2.96% of the shares, roughly 2.55 shares worth around $174.36 million.
